Listeriolysin O, alone and in combination with Cisplatin and Carfilzomib, modulates MDR۱, MRP۱, and BCRP expression in Cisplatin-sensitive and -resistant ovarian cancer cells

سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 30

فایل این مقاله در 10 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJPM-5-3_003

تاریخ نمایه سازی: 21 آبان 1405

چکیده مقاله:

Background: Overexpression of ABC efflux transporters (MDR۱, MRP۱, BCRP) drives chemoresistance in ovarian cancer. We test a novel strategy combining the pore-forming toxin LLO with cisplatin and carfilzomib to overcome multidrug resistance.Objectives: This study aimed to evaluate the effects of LLO, both alone and in combination with Cis and CFZ, on the mRNA expression levels of MDR۱, MRP۱, and BCRP in cisplatin-sensitive (A۲۷۸۰S) and cisplatin-resistant (A۲۷۸۰CisR) human ovarian carcinoma cell lines.Methods: In this experimental study, A۲۷۸۰S and A۲۷۸۰CisR cells were treated for ۷۲ hours with LLO, Cis, CFZ, and their combinations (Cis/LLO, CFZ/LLO, Cis/CFZ/LLO). The relative mRNA expression levels of MDR۱, MRP۱, and BCRP were quantified using quantitative real-time PCR (qRT-PCR), with normalization to the GAPDH housekeeping gene. Statistical analysis was performed using one-way ANOVA followed by Tukey's post-hoc test.Results: LLO monotherapy had a minimal impact on transporter expression. In stark contrast, all combination regimens induced a profound and statistically significant downregulation of MDR۱, MRP۱, and BCRP mRNA in both cell lines (p < ۰.۰۵ for overall treatment effect). The triple-combination therapy (Cis/CFZ/LLO) was the most potent, demonstrating the strongest suppression. The dual combination of CFZ/LLO was also highly effective. Notably, combinations involving CFZ were consistently potent in both sensitive and resistant cells, while the Cis/LLO combination showed differential efficacy, being less effective in A۲۷۸۰CisR cells.Conclusion: LLO acts as a powerful chemosensitizing agent that, in combination with cisplatin and carfilzomib, drastically downregulate the expression of critical ABC efflux transporters. This multi-mechanistic strategy, which concurrently targets DNA integrity, proteasome function, and plasma membrane stability, effectively overcomes a cornerstone of chemoresistance in ovarian cancer cells and represents a highly promising therapeutic approach for cisplatin-resistant disease.

کلیدواژه ها:

نویسندگان

- -

Department of Clinical Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

- -

Department of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

- -

Department of Laboratory Sciences, Faculty of Paramedicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

- -

Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

- -

Department of Clinical Biochemistry, Faculty of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

- -

Molecular Medicine Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :